Schubert & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Schubert & Co’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	1310
2021 Q4	$0	Buy	+1	New	+$9	﹤0.01%	1256

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Schubert & Co's SGMO Position: Q1 2022 in Review

Schubert & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2022, closing a stake of 1 share.

Schubert & Co first reported a position in SGMO in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 195 funds tracked by Wall St. Rank hold SGMO as of Q1 2022.

Schubert & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2022 after selling out during the quarter.
Schubert & Co sold 1 SANGAMO THERAPEUTICS INC share in Q1 2022.
Schubert & Co first reported a position in SANGAMO THERAPEUTICS INC in Q4 2021 and held it in 1 quarter.
Schubert & Co's SANGAMO THERAPEUTICS INC position peaked at $0 in Q4 2021.
195 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2022.

Based on Schubert & Co's 13F filing for Q1 2022, filed 16 May 2022.